PMID- 22280536
OWN - NLM
STAT- MEDLINE
DCOM- 20121210
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 8
DP  - 2012 Aug
TI  - Present status and perspectives in functional analysis of p53 in chronic 
      lymphocytic leukemia.
PG  - 1445-51
LID - 10.3109/10428194.2012.660630 [doi]
AB  - Aberrations of TP53 (mutations and/or deletions) are associated with a dismal 
      prognosis in chronic lymphocytic leukemia (CLL). Complete loss of ATM is another 
      mechanism of failed DNA damage response and also associated with poorer prognosis 
      in CLL. However, p53 dysfunction may arise through alternative mechanisms 
      unrelated to structural aberrations (deletion and/or mutation) of TP53 or ATM, 
      and thus be undetectable by traditional DNA-directed approaches (fluorescence in 
      situ hybridization [FISH], sequencing, karyotyping). In order to address the 
      latter changes, and also to better understand the consequences of TP53/ATM 
      aberrations, p53 functional assays have recently been developed. The purpose of 
      dynamic assessment of p53 response in CLL is to carry out a comprehensive 
      analysis of all mechanisms causing p53-deficient phenotype, including those 
      unrelated to genomic aberrations of TP53 and ATM. The present review focuses on 
      the current knowledge of p53 function assays in CLL, including important features 
      such as technical issues, correlation with structural aberrations and clinical 
      value.
FAU - de Viron, Emeline
AU  - de Viron E
AD  - De Duve Institute, Universite catholique de Louvain, Brussels, Belgium.
FAU - Michaux, Lucienne
AU  - Michaux L
FAU - Put, Natalie
AU  - Put N
FAU - Bontemps, Francoise
AU  - Bontemps F
FAU - Van Den Neste, Eric
AU  - Van Den Neste E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20120301
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (MIRN34 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Cytogenetics
MH  - DNA Damage
MH  - Gene Deletion
MH  - *Gene Expression Regulation, Leukemic
MH  - *Genes, p53
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics
MH  - MicroRNAs/genetics
MH  - Phenotype
MH  - Prognosis
MH  - Tumor Suppressor Protein p53/*genetics
EDAT- 2012/01/28 06:00
MHDA- 2012/12/12 06:00
CRDT- 2012/01/28 06:00
PHST- 2012/01/28 06:00 [entrez]
PHST- 2012/01/28 06:00 [pubmed]
PHST- 2012/12/12 06:00 [medline]
AID - 10.3109/10428194.2012.660630 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 Aug;53(8):1445-51. doi: 10.3109/10428194.2012.660630. Epub 
      2012 Mar 1.